Advertisement
Canada markets open in 6 hours 25 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7267
    +0.0004 (+0.05%)
     

  • CRUDE OIL

    83.90
    +1.17 (+1.41%)
     

  • Bitcoin CAD

    89,254.37
    +5,076.19 (+6.03%)
     

  • CMC Crypto 200

    1,315.65
    +3.03 (+0.23%)
     

  • GOLD FUTURES

    2,400.40
    +2.40 (+0.10%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,433.25
    -114.00 (-0.65%)
     

  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     

  • FTSE

    7,877.05
    0.00 (0.00%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6823
    +0.0002 (+0.03%)
     

Why Tilray (TLRY) Could Be Positioned for a Slump

Zacks

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Tilray, Inc. TLRY, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in TLRY.

A key reason for this move has been the negative trend in earnings estimates revisions. For the full year, we have seen three estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of 48 cents a share a month ago to its current level of a loss of 57 cents.

Also, for the current quarter, the consensus estimate went down to a loss of 14 cents a share from a loss of 12 cents over the past 30 days.

The stock also has seen some pretty dismal trading lately, as the share price has dropped 15.5% in the past month.

Tilray, Inc. Price and Consensus

Tilray, Inc. Price and Consensus | Tilray, Inc. Quote

ADVERTISEMENT

So, it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long-time horizon to wait.

If you are still interested in the Medical – Drugs industry, you may instead consider a better-ranked stock - BioSpecifics Technologies Corp. BSTC. The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank stocks here.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BioSpecifics Technologies Corp (BSTC) : Free Stock Analysis Report
 
Tilray, Inc. (TLRY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research